Keros Therapeutics, Inc. (KROS) Balance Sheet

The trajectory shows a balance sheet built on capital raises being systematically consumed rather than replenished: cash has declined every quarter since 2025Q1, and the last two quarters alone show roughly $24M and $24M sequential drawdowns, which appears consistent with the R&D-led operating losses documented in the income statement. Total debt has drifted down slightly from $19.3M to $15.7M and total liabilities from $46.4M to $25.3M, so the erosion is not credit-driven but purely cash-consumption-driven. Investors should note that each quarter the company remains pre-commercial, its balance sheet quality is defined less by the current cash level than by whether collaboration receipts arrive before the cushion thins further.

Total liabilities stand at just $25.3M against $257.6M of cash, meaning the company has no apparent near-term solvency pressure or refinancing exposure, and the current ratio is essentially a cash ratio in disguise. However, that ratio's extreme reading reflects an absence of working-capital obligations rather than operating scale, and the buffer is a wasting asset: on recent burn rates, the cash position implies only a few years of runway if collaboration receipts do not recur. The judgment call for analysts is whether to anchor on the absolute cash figure, which looks comfortable in isolation, or on the direction of travel, which has been consistently negative across five consecutive quarters.

The asset mix confirms a capital-light structure where the balance sheet is essentially a treasury account, with PPE shrinking quarter after quarter while capex of under $1M per quarter indicates depreciation is running ahead of reinvestment. The complete absence of goodwill means there is no intangible overhang or impairment overhang to monitor, which removes a common risk factor that peers such as acquisitive developers carry. The flip side is that the asset base offers no operational ballast: if the clinical pipeline stalls, there is little in the way of tangible or contractual assets to fall back on beyond the remaining cash.

Because retained earnings are deeply negative and the deficit expands by roughly $25-30M per quarter, book equity is a declining residual that would erode further if losses continue at the observed pace, and any per-share equity metric must be weighed against ongoing SBC issuance running at $5.4-9.2M per quarter. The absence of buybacks or dividends, consistent with the capital-preservation posture seen in the cash flow statements, means equity is not being shrunk from below but is being quietly consumed from within by operating losses. The low 0.06x D/E reading, meanwhile, is more an artifact of large equity funding than of operational deleveraging.

The zero deferred revenue balance across recent quarters means there is no pre-existing booked revenue set to convert into income in coming periods, which reinforces the income statement finding that topline depends on episodic, deal-specific transactions rather than recurring billing. The absence of a disclosed RPO figure in the data provided limits visibility further, so analysts cannot gauge the size of any contracted backlog and should treat forward revenue visibility as essentially closed. This has direct balance sheet implications: with no contracted inflow to underwrite the burn, the cash trajectory will remain hostage to milestone timing rather than management spending control.